AMG enters the week with one of its more notable short-interest retreats of the year, even as the stock barely moved and the Street's price targets sit well above current levels.
Short interest has collapsed over the past two sessions. Estimated shares short fell 33% over the week to just 2.4% of the free float — down from roughly 3.6% a week ago and the lowest level in at least six weeks. The drop accelerated Tuesday, with a 22% single-session decline suggesting a deliberate unwind rather than a drift. At these levels, short positioning is modest rather than meaningful. Cost to borrow has retreated in parallel, easing to 0.32% — its lowest reading in a month — and availability remains loose, consistent with a borrow market under little strain. The ORTEX short score has moved in the same direction, dropping to 32.4 from above 37 just ten days ago.
Options tell a mildly cautious story, though not an alarming one. The put/call ratio nudged up to 1.13, fractionally above its 20-day average of 1.11, with a z-score of just 0.5. That's within entirely normal range. Compare that to early April, when the PCR spiked above 1.52 during the broad market dislocation — the ratio has since normalised and is nowhere near signalling elevated stress. The RSI sits at 56, pointing to a market that is neither overbought nor oversold.
The Street remains firmly constructive, and the gap between the current price and consensus targets is wide. TD Cowen reiterated its Buy on Wednesday at a $454 target — a 51% premium to the close of $301.53 — following a modest target trim from $463 to $454 after the May 4 earnings print. Barrington Research held its Outperform with a $365 target. The mean target across analysts is $385.71, implying roughly 28% upside. The post-earnings reaction confirms the positive bias: AMG gained 4.3% the day after its Q1 report on May 4 and added 3.5% over the subsequent five sessions. The bull case centres on AUM growth to $803.6 billion, 15% EPS expansion, and aggressive share repurchases — AMG has cut its share count by nearly 12% year-on-year. Valuation multiples are not stretched: the P/E is around 8.3x and EV/EBITDA is 8.8x, with EV/EBITDA easing roughly 0.3x over the past month. EPS momentum factor scores rank in the 82nd–85th percentile, pointing to persistent estimate upgrades.
The most notable insider signal in recent weeks is actually mixed at the senior level. Director David Ryan sold just over $1 million in shares on May 6, and another director sold $300k three days later on May 8. However, a separate director bought $459k on the same day as Ryan's sale. Looking further back, the CEO Jay Horgen received a substantial equity award in March and has built holdings to over 570,000 shares, suggesting alignment between management and shareholders even if headline cash flow from directors has been net negative in recent weeks. The 90-day net insider position is modestly positive in share terms, at around 46,000 net shares bought.
AMG's closest peers have diverged this week. OWL dropped nearly 7% over seven days — a sharper pullback than AMG's 0.7% weekly decline. IVZ gained 5.8% and BLK added 4.2%, reflecting appetite for diversified asset managers in a firming tape. AMG's relative underperformance against the broader peer group, despite a clean earnings beat, keeps the gap-to-target question in focus. Next earnings are scheduled for July 27 — the window between now and then is where the convergence narrative either builds or stalls.
See the live data behind this article on ORTEX.
Open AMG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
